Transcranial Magnetic Stimulation and Pharmacologic/Probiotic Interventions for Diarrhea-Predominant IBS

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-30

Study Completion Date

2026-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

What is the study about? This study is for adults with diarrhea-predominant irritable bowel syndrome (IBS-D) who suffer from chronic visceral pain. We aim to investigate whether combining two different treatment approaches is more effective in alleviating IBS-D symptoms than either treatment alone. The first treatment is a non-invasive brain stimulation technique called repetitive Transcranial Magnetic Stimulation (rTMS), while the second treatment involves either an intestinal antispasmodic medication (Pinaverium Bromide) or a probiotic (Bifidobacterium).

What will participants do?

Participants will be randomly assigned by a computer to one of four groups:

1. Group 1: Receive real rTMS sessions + take Pinaverium Bromide pills.
2. Group 2: Receive real rTMS sessions + take Bifidobacterium pills.
3. Group 3: Receive fake (sham) rTMS sessions + take Pinaverium Bromide pills.
4. Group 4: Receive fake (sham) rTMS sessions + take Bifidobacterium pills.

Neither the participant nor the doctor giving the treatments will know which group the participant is in for the rTMS part (this is called "blinding"). The study will involve several weeks of treatment and follow-up visits to track symptoms.

What are the potential benefits and risks? Potential Benefits: Participants may experience a reduction in their abdominal pain, diarrhea, and other IBS symptoms. However, benefit cannot be guaranteed. The information from this study may help other IBS patients in the future.

Potential Risks: rTMS is generally safe but may cause mild headache, scalp discomfort, or lightheadedness. The medications may have side effects like any drug, which will be explained in detail before the study starts.

Why is this study important? This is the first study to test how brain stimulation and gut-focused treatments work together for IBS pain. The results could lead to new and more effective combination therapies for people who don't get enough relief from current treatments.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Repeated Transcranial Magnetic Stimulation Combined With a Live Probiotic Tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live) in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

NCT06960369

Irritable Bowel Syndrome Irritable Bowel Syndrome With Diarrhea (IBS-D) Repetitive Transcranial Magnetic Stimulation (rTMS) +3 more

RECRUITING PHASE1

Repetitive Transcranial Magnetic Stimulation in Irritable Bowel Syndrome

NCT01801605

Irritable Bowel Syndrome

COMPLETED PHASE2

Influence of Ear Vagus Nerve Stimulator on Patients With IBS

NCT06321237

Irritable Bowel Syndrome

NOT_YET_RECRUITING NA

Irritable Bowel Syndrome (IBS) Functional Magnetic Resonance Imaging (fMRI) With Desipramine

NCT00880594

Irritable Bowel Syndrome

TERMINATED NA

Neural Circuit Mechanism of Inflammatory Bowel Disease Combined With Depression

NCT06471894

Inflammatory Bowel Diseases

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicenter, randomized, double-blind, sham-controlled, 2x2 factorial trial investigating the efficacy of combining repetitive Transcranial Magnetic Stimulation (rTMS) with gut-directed therapy for chronic visceral pain in diarrhea-predominant irritable bowel syndrome (IBS-D).

Scientific rationale: Current treatments for IBS-D often provide inadequate relief. rTMS, a non-invasive neuromodulation technique, may alleviate pain by restoring cortical excitability and neural plasticity. Its potential synergy with gut-targeted agents (antispasmodic or probiotic) remains unexplored.

Objectives: The primary objective is to determine the interaction effect between rTMS (real vs. sham) and drug (pinaverium bromide vs. bifidobacterium) on the composite response rate at Week 2. Secondary objectives include assessing changes in IBS-SSS, IBS-QoL, PHQ-9 scores, and anorectal manometry parameters.

Methodology: 140 eligible adults will be randomized equally into four groups: (1) real rTMS + pinaverium bromide, (2) real rTMS + bifidobacterium, (3) sham rTMS + pinaverium bromide, (4) sham rTMS + bifidobacterium. Real rTMS will be delivered at 1Hz, 80% MT over the mPFC for 20 minutes daily for 2 weeks. Sham rTMS uses a placebo coil. Pinaverium bromide (50mg tid) and bifidobacterium (500mg bid) will be administered with matched placebos to maintain blinding. Participants, outcome assessors, and statisticians will be blinded to intervention assignments.

Outcomes: The primary outcome is the proportion of participants achieving composite response (≥30% reduction in worst abdominal pain AND ≥50% reduction in days with BSFS 6/7 stools) at Week 2. Secondary outcomes include changes from baseline in IBS-SSS, IBS-QoL, PHQ-9, and manometry measures.

Statistics: A factorial ANOVA will be used to test the main and interaction effects. The primary analysis will follow the intention-to-treat principle.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

IBS (Irritable Bowel Syndrome)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

An independent researcher will generate a randomized sequence using an online tool (https://www.sealedenvelope.com/simple-randomiser/v1/lists) with 1:1:1:1 allocation stratified by center. The attending physician will open sealed envelopes before treatment to assign participants to one of four groups: rTMS with pinaverium, rTMS with Bifidobacterium, sham with pinaverium, or sham with Bifidobacterium. Block randomization (block size=4) ensures balance across centers.

For blinding, identical capsules conceal medications from patients and outcome assessors. Participants are blinded to real/sham rTMS due to identical auditory cues. rTMS operators are unblinded but excluded from outcome assessment. All other personnel remain blinded.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active rTMS + Pinaverium Bromide Group

Participants in this arm will receive active repetitive Transcranial Magnetic Stimulation (rTMS) sessions and oral Pinaverium Bromide tablets.

Group Type EXPERIMENTAL